Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, has announced that it will be presenting at H.C. Wainwright & Co.’s Psychedelics in Psychiatry and Beyond conference. The virtual event will be held on June 17, 2021. At the elite conference, Tryp chair and CEO Greg McKee will present an overview of the business including the company’s pipeline, which features its psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program for chronic pain and eating disorder indications. McKee’s prerecorded presentation will be available beginning 7 a.m. EDT on the day of the conference. In addition, Tryp announced the adoption of a new form of stock option plan designed to align with certain U.S. regulatory requirements pursuant to the U.S. Internal Revenue Code. As a result, some company directors and officers who were granted stock options under the prior plan have requested that those options be cancelled and re-issued under the new plan. Tryp has obtained approval from the Canadian Securities Exchange for the move.
To register for the event, visit https://ibn.fm/DkhtI
To view the full press release, visit https://ibn.fm/OnzGf
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing compounds for the treatment of diseases with accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with the Dr. Jennifer Miller at the University of Florida. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to Tare available in the company’s newsroom at https://ibn.fm/TRYPF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.